Literature DB >> 15889359

Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area.

Jose M Eguia1, Catherine Liu, Matthew Moore, Elizabeth M Wrone, Joan Pont, Julie L Gerberding, Henry F Chambers.   

Abstract

BACKGROUND: Staphylococcus aureus exhibits varying degrees of reduced vancomycin susceptibility, and strains with intermediate levels of resistance are thought to emerge by antibiotic selection of subpopulations in heterogeneously resistant precursor strains exposed to this antibiotic. We sought to determine the prevalence of and risk factors for carriage of potential heterogeneous vancomycin-intermediate S. aureus (hVISA).
METHODS: We prospectively observed a cohort of 211 patients undergoing hemodialysis and performed quarterly surveillance cultures for up to 2 years. We screened for reduced vancomycin susceptibility using brain-heart infusion agar with 4 microg/mL vancomycin.
RESULTS: We identified 10 colonizing potential hVISA isolates recovered from 7 patients among both methicillin-susceptible and methicillin-resistant S. aureus strains. No confirmed hVISA isolates were identified; we can be 95% certain that the prevalence of confirmed hVISA carriage does not exceed 1.4%. When compared with noncolonized hemodialysis patients, neither vancomycin exposure, duration of hospitalization, nor any baseline clinical or demographic factor was found to predict colonization with potential hVISA on univariate analyses; increased number of months receiving hemodialysis was associated with potential hVISA colonization on multivariate analysis.
CONCLUSIONS: Despite numerous published reports of S. aureus with reduced vancomycin susceptibility, carriage of these isolates remains a rare phenomenon. Given the unclear clinical significance of potential hVISA, it is not clear whether clinical laboratories should identify such strains, or how they should do so.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15889359     DOI: 10.1086/429906

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

1.  Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans.

Authors:  Susan L Fink; Richard A Martinello; Sheldon M Campbell; Thomas S Murray
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

Review 2.  Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.

Authors:  Sebastiaan J van Hal; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Methicillin and Vancomycin Resistant S. aureus in Hospitalized Patients.

Authors:  Poonam Sood Loomba; Juhi Taneja; Bibhabati Mishra
Journal:  J Glob Infect Dis       Date:  2010-09

4.  Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections.

Authors:  Julia C Dombrowski; Lisa G Winston
Journal:  J Infect       Date:  2008-06-03       Impact factor: 6.072

5.  Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center.

Authors:  Yasmin Maor; Galia Rahav; Natasha Belausov; Debby Ben-David; Gill Smollan; Nathan Keller
Journal:  J Clin Microbiol       Date:  2007-03-07       Impact factor: 5.948

6.  Intermediate vancomycin susceptibility in a community-associated MRSA clone.

Authors:  Christopher J Graber; Margaret K Wong; Heather A Carleton; Françoise Perdreau-Remington; Barbara L Haller; Henry F Chambers
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

Review 7.  Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.

Authors:  Shanshan Zhang; Xiaoxi Sun; Wenjiao Chang; Yuanyuan Dai; Xiaoling Ma
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.